1、 Sattler S, Smits HH, Xu D, et al. The evolutionary role of the IL-33/ST2 system in host immune defence[J]. Archivum immunologiae et therapiae experimentalis, 2013, 61(2): 107-117. Sattler S, Smits HH, Xu D, et al. The evolutionary role of the IL-33/ST2 system in host immune defence[J]. Archivum immunologiae et therapiae experimentalis, 2013, 61(2): 107-117.
2、 刘曦. 细胞因子 IL-33 与受体相互作用的结构生物学研究[D]. 清华大学, 2013. 刘曦. 细胞因子 IL-33 与受体相互作用的结构生物学研究[D]. 清华大学, 2013.
3、 Rüger K, Ottenlinger F, Schr?der M, et al. Modulation of IL-33/ST2-TIR and TLR signaling pathway by fingolimod and analogs in immune cells[J]. Scandinavian journal of immunology, 2014,80(6):398-407. Rüger K, Ottenlinger F, Schr?der M, et al. Modulation of IL-33/ST2-TIR and TLR signaling pathway by fingolimod and analogs in immune cells[J]. Scandinavian journal of immunology, 2014,80(6):398-407.
4、 Breidthardt T, Balmelli C, Twerenbold R, et al. Heart failure therapy-Induced early ST2 changes may offer long-Term therapy guidance[J]. Journal of cardiac failure, 2013, 19(12): 821-828. Breidthardt T, Balmelli C, Twerenbold R, et al. Heart failure therapy-Induced early ST2 changes may offer long-Term therapy guidance[J]. Journal of cardiac failure, 2013, 19(12): 821-828.
5、 Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker[J]. Nature reviews Drug discovery, 2008, 7(10): 827-840. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker[J]. Nature reviews Drug discovery, 2008, 7(10): 827-840.
6、 Schulte S, Sukhova GK, Libby P. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis[J]. The American journal of pathology, 2008, 172(6): 1500-1508. Schulte S, Sukhova GK, Libby P. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis[J]. The American journal of pathology, 2008, 172(6): 1500-1508.
7、 Pylaeva EA, Potekhina AV, Provatorov SI, et al. Effector and regulatory blood lymphocyte subpopulations in stable coronary artery disease[J]. Atherosclerosis, 2014, 235(2): e151. Pylaeva EA, Potekhina AV, Provatorov SI, et al. Effector and regulatory blood lymphocyte subpopulations in stable coronary artery disease[J]. Atherosclerosis, 2014, 235(2): e151.
8、 Eren E, Ellidag HY, Aydin O, et al. HDL functionality and crystal-based sterile inflammation in atherosclerosis[J]. Clinica Chimica Acta, 2015,439:18-23. Eren E, Ellidag HY, Aydin O, et al. HDL functionality and crystal-based sterile inflammation in atherosclerosis[J]. Clinica Chimica Acta, 2015,439:18-23.
9、 Chen O, Patel J, Mohamed E, et al. The immunoregulatory role of cytokines in congestive heart failure[J]. Interdiscip J Microinflammation, 2014, 1(111): 2. Chen O, Patel J, Mohamed E, et al. The immunoregulatory role of cytokines in congestive heart failure[J]. Interdiscip J Microinflammation, 2014, 1(111): 2.
10、 Taleb S, Herbin O, Ait-Oufella H, et al. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis[J]. Arterioscler Thrombosis Vasc Biol, 2007, 27(12): 2691-2698. Taleb S, Herbin O, Ait-Oufella H, et al. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis[J]. Arterioscler Thrombosis Vasc Biol, 2007, 27(12): 2691-2698.
11、 Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger[J]. Journal of leukocyte biology, 2007, 81(1): 1-5. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger[J]. Journal of leukocyte biology, 2007, 81(1): 1-5.
12、 Miller AM, Liew FY. The IL-33/ST2 pathway-a new therapeutic target in cardiovascular disease[J]. Pharmacology & therapeutics, 2011, 131(2): 179-186. Miller AM, Liew FY. The IL-33/ST2 pathway-a new therapeutic target in cardiovascular disease[J]. Pharmacology & therapeutics, 2011, 131(2): 179-186.
13、 Krishna NR, Sushma M. Pathopysolgy and pharmacotherapy of atherosclerosis[M]. 2014. Krishna NR, Sushma M. Pathopysolgy and pharmacotherapy of atherosclerosis[M]. 2014.
14、 Wei Z, Tong B, Xia Y, et al. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 pathways[J]. PloS one, 2013, 8(3): e59171. Wei Z, Tong B, Xia Y, et al. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 pathways[J]. PloS one, 2013, 8(3): e59171.
15、 Rehman S U, Mueller T, Januzzi JL. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure[J]. Journal of the American College of Cardiology, 2008, 52(18): 1458-1465. Rehman S U, Mueller T, Januzzi JL. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure[J]. Journal of the American College of Cardiology, 2008, 52(18): 1458-1465.
16、 向志光, 张连峰. IL-33 及其受体 ST2 的研究进展[J]. 中国比较医学杂志, 2009, 19(9): 59-62. 向志光, 张连峰. IL-33 及其受体 ST2 的研究进展[J]. 中国比较医学杂志, 2009, 19(9): 59-62.
17、 Dez J. Serum soluble ST2 as a biochemical marker of acute heart failure: future areas of research[J]. J Am Coll Cardiol,2008,52(18): 1466-1467. Dez J. Serum soluble ST2 as a biochemical marker of acute heart failure: future areas of research[J]. J Am Coll Cardiol,2008,52(18): 1466-1467.
18、 Foks AC, Lichtman AH, Kuiper J. Treating atherosclerosis with regulatory T cells[J]. Arterioscler Thrombosis Vasc Biol, 2014(114):303568. Foks AC, Lichtman AH, Kuiper J. Treating atherosclerosis with regulatory T cells[J]. Arterioscler Thrombosis Vasc Biol, 2014(114):303568.
